Browse the evidence

SGLT2 inhibitors protect kidney function by restoring tubuloglomerular feedback, which reduces glomerular hyperfiltration and intraglomerular pressure, thereby indirectly reducing cardiovascular disease risk.

SGLT2 inhibitors protect your kidneys by reducing pressure inside the kidney filters, which also helps protect your heart, as kidney health is closely linked to heart health.

Menopausal hormone therapy (MHT) containing estrogen does not reduce cardiovascular disease risk and may increase stroke risk in women with type 2 diabetes, making it unsuitable for primary prevention.

Do not use estrogen patches or pills to protect your heart if you have diabetes. While they help with hot flashes, they do not prevent heart attacks and may increase stroke risk. Focus on blood pressure, lipids, and blood sugar control instead.

GIP promotes triglyceride storage in white adipose tissue and may contribute to ectopic fat accumulation (fatty liver) in mice, acting as an obesogenic hormone in this context.

Endogenous GIP promotes fat storage in adipose tissue, particularly with high-sugar/high-fat diets. This 'obesogenic' effect is part of the biological puzzle that dual GIP/GLP-1 drugs must navigate to achieve net weight loss.

High-fat diets (HFD) induce insulin resistance in rodents primarily through the accumulation of diacylglycerol (DAG) and ceramides, which inhibit insulin signaling via PKC and PP2A activation respectively.

This explains why high-fat diets can lead to metabolic issues at a cellular level: excess fat storage in organs like the liver and muscle triggers specific molecules (DAG and ceramides) that block insulin's ability to signal for glucose uptake.

Bariatric surgery does NOT significantly reduce the incidence of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma compared to conventional treatment.

While bariatric surgery reduces many obesity-related cancers, it does not appear to significantly lower the risk of esophageal, gastric, thyroid, kidney, prostate cancers, or multiple myeloma.

Racial and ethnic minorities, particularly Black and American Indian/Alaskan Native individuals, have significantly lower initiation rates of newer diabetes medications (GLP-1RAs, DPP-4Is, SGLT-2Is) compared to White individuals, independent of socioeconomic factors.

If you are a minority patient with type 2 diabetes, you may face systemic barriers to accessing newer, highly effective medications like GLP-1s or SGLT-2 inhibitors, even if you have insurance. These drugs offer significant cardiovascular and kidney benefits. It is crucial to discuss these options with your provider, understand your insurance formulary, and advocate for yourself, as disparities in initiation are well-documented and often driven by systemic factors rather than medical necessity.

Brainstem cholecystokinin-expressing (CCKAP/NTS) neurons are necessary for GLP-1 receptor agonists to induce conditioned taste avoidance (nausea/aversive effects).

The nausea and aversion caused by GLP-1 medications are mediated by specific brainstem neurons (CCKAP/NTS). Blocking these neurons prevents the aversive response, confirming that nausea is a central brain effect, not just a stomach issue. This knowledge helps in managing expectations and potentially developing strategies to reduce nausea.

Genetic disruption of AMPK-glycogen binding in skeletal muscle (via AMPK beta2 subunit mutation) leads to increased adiposity and impaired glucose handling, whereas disruption in liver (via AMPK beta1 subunit mutation) primarily increases hepatic fat deposition without affecting whole-body glucose handling.

This research highlights that the body's energy sensors (AMPK) rely on glycogen stores for stability. Disrupting this link impairs metabolic health. While this is a genetic model, it suggests that maintaining healthy glycogen stores through balanced carbohydrate intake and regular physical activity is crucial for optimal metabolic function and preventing ectopic fat accumulation.

Traditional nontargeted weight management strategies (lifestyle changes, anti-obesity medications, and metabolic/bariatric surgery) are frequently inadequate for patients with highly penetrant monogenic or syndromic obesity caused by rare genetic variants in the melanocortin-4 receptor (MC4R) pathway.

If you have severe, early-onset obesity and insatiable hunger (hyperphagia) that persists despite strict dieting or surgery, standard approaches may not work because of a genetic disruption in your brain's hunger signals. You should seek genetic testing and specialized care to access targeted therapies (like setmelanotide) that address the root hormonal cause rather than just calories.

Genetically proxied activation of the glucagon-like peptide-1 receptor (GLP1RA) is causally associated with a reduced risk of schizophrenia.

This study suggests that medications activating the GLP-1 receptor (like semaglutide or liraglutide) may lower the risk of developing schizophrenia, primarily through their effect on body weight. For individuals at high risk of schizophrenia who are overweight, using these medications for weight management might offer a dual benefit of metabolic health and reduced psychiatric risk. However, this is based on genetic data, not direct clinical trials, so it should not replace standard psychiatric care.

Non-sulfated CCK peptides stimulate gastric acid secretion via CCK2 receptors, acting similarly to gastrin, whereas sulfated CCK inhibits acid secretion via CCK1 receptors.

The form of CCK matters. In rare tumors (CCKoma), non-sulfated CCK can cause ulcers by stimulating acid. In healthy individuals, sulfated CCK inhibits acid. This distinction is crucial for understanding gastric pathologies.

Twelve weeks of dapiglutide (4 mg or 6 mg) once weekly does not produce a statistically significant reduction in body weight compared to placebo in adults with obesity.

In this study, taking 4 mg or 6 mg of dapiglutide once weekly for 12 weeks did not lead to significant weight loss compared to a placebo in people with obesity. The drug was safe, but the dose might be too low or the treatment period too short to see results. Future studies may need higher doses or longer durations.

Emergency department exposures to GLP-1 and GLP-1/GIP receptor agonists predominantly result in mild, self-limiting gastrointestinal symptoms (nausea, vomiting) that typically resolve within 8 to 24 hours with supportive care.

If you or someone else takes too much of a GLP-1 medication (like Ozempic or Wegovy), expect nausea and vomiting. These symptoms are usually mild and go away within a day. Focus on hydration and rest. Seek medical help if you feel faint, have severe abdominal pain, or cannot keep fluids down.

YouTube videos on semaglutide (Ozempic/Wegovy) largely fail to adequately communicate critical safety risks, specifically the risk of aspiration during anesthesia, the persistence of side effects due to the drug's long half-life, the risk of counterfeit drugs, and the lack of long-term data.

Do not rely on YouTube videos for safety information about semaglutide. They often miss critical risks like aspiration during surgery, the persistence of side effects due to the drug's long half-life, and the danger of counterfeit products. Always consult a physician for personalized advice and safety monitoring.

Childhood adversities are associated with an increased risk of fatal or non-fatal CHD events in adulthood.

Early life trauma has long-lasting physical consequences, increasing the risk of heart disease later in life. While you cannot change your childhood, being aware of this risk factor allows for more proactive cardiovascular monitoring and stress management in adulthood.

Semaglutide 0.4 mg does not significantly improve liver fibrosis stage compared to placebo in patients with NASH and fibrosis stage F2 or F3.

For patients with NASH and fibrosis stages F2 or F3, treatment with 0.4 mg of subcutaneous semaglutide daily for 72 weeks does not significantly improve liver fibrosis stage compared to placebo, despite improving NASH resolution. This suggests that while semaglutide is effective for resolving NASH, it may not be sufficient for reversing fibrosis in all patients.

Maternal consumption of a high-fat diet during gestation and lactation causes hypothalamic inflammation and altered neural projections in offspring, predisposing them to obesity and metabolic disorders.

For expectant mothers, avoiding high-fat diets during pregnancy and breastfeeding may help prevent metabolic programming issues in the child, such as altered brain circuits that regulate hunger.

Intermittent administration of senolytic drugs (Dasatinib + Quercetin) or genetic clearance of senescent cells alleviates obesity-induced metabolic dysfunction, including insulin resistance and glucose intolerance, in obese mice.

This research suggests that targeting senescent cells (cells that have stopped dividing and secrete inflammatory factors) using specific drug combinations (like Dasatinib and Quercetin) or genetic methods can improve metabolic health in obesity. While not yet a standard human treatment, it highlights senolytics as a potential future therapy for obesity-related diabetes and inflammation.

Reduced sensitivity to light due to lens yellowing and reduced SCN neuronal coupling contributes to the desynchronization of peripheral clocks and weakened circadian output in older adults.

Your eyes let in less blue light as you age, weakening your body's time signal. Maximizing morning outdoor light exposure can help compensate for this reduced sensitivity and strengthen your circadian rhythm.

In Type 1 Diabetes (T1D), functional impairment of beta cells occurs early in the prediabetic phase, whereas a substantial decrease in beta cell mass occurs late, close to clinical manifestation.

For T1D, preserving existing beta cell function early is as critical as replacing mass later. Treatments aiming to restore function (like those inducing the 'honeymoon phase') may be more effective if applied early, before massive cell death occurs.

Surgical removal of adipose tissue and specific genetic modifications (e.g., deletion of diacylglycerol acyltransferase 1) extend lifespan in rodents.

In rodents, removing fat or modifying specific fat-synthesis genes extends life. This highlights the critical role of adipose tissue in aging. For humans, this suggests that managing body fat levels is crucial for healthspan, though surgical removal is not a viable longevity strategy.

Exposure to Endocrine-Disrupting Chemicals (EDCs) such as Bisphenol A (BPA) and Diethylstilbestrol (DES) during fetal development can cause transgenerational epigenetic changes leading to increased risks of cancer, obesity, and reproductive disorders in offspring and subsequent generations.

Minimize exposure to endocrine disruptors like BPA (found in some plastics) and DES-like compounds. Use glass or stainless steel containers for food storage, avoid heating food in plastic, and choose fresh foods over canned when possible to reduce intake of these chemicals, especially during pregnancy.

DPP-IV inhibitors (e.g., sitagliptin) lack strong clinical evidence for improving NAFLD/NASH histology and may be ineffective in controlled trials, despite promising animal model data.

Do not rely on DPP-IV inhibitors (like sitagliptin) to treat your liver disease. While they help with blood sugar, controlled studies show they do not significantly improve liver fat or inflammation in NAFLD/NASH patients.

Pharmacological inhibition of mTOR via rapamycin extends lifespan across multiple model organisms, including yeast, nematodes, fruit flies, and mice.

This paper establishes that inhibiting the mTOR pathway, specifically via rapamycin, extends lifespan in various animals. While this is a key finding in longevity research, the paper notes that translating this to humans requires understanding the complex interplay with nutrient sensing and potential side effects, as rapamycin is an immunosuppressant.